Article Text

PDF
THU0233 Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1)
  1. X. Baraliakos1,
  2. J. Braun1,
  3. J. Sieper2,
  4. D.L. Baeten3,
  5. A. Readie4,
  6. G. Ligozio4,
  7. H. Richards5
  1. 1Rheumazentrum Ruhrgebiet, Herne
  2. 2Charité University Medicine Berlin, Berlin, Germany
  3. 3Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
  4. 4Novartis Pharmaceuticals Corporation, East Hanover, United States
  5. 5Novartis Pharma AG, Basel, Switzerland

Abstract

Background MEASURE 1 (NCT01358175) is a randomized, double-blind, placebo (PBO)-controlled trial that has demonstrated the efficacy and safety of secukinumab, a human anti–interleukin-17A monoclonal antibody, in subjects with active ankylosing spondylitis (AS).1

Objectives To investigate the effect of secukinumab on objective signs of inflammation in the sacroiliac (SI) joints and spine at Weeks (Wks) 16 and 52 using magnetic resonance imaging (MRI) in the MEASURE 1 study.

Methods 371 adults with active AS were randomized to secukinumab or PBO: i.v. secukinumab 10 mg/kg (Wks 0, 2, 4) followed by s.c. secukinumab 75 mg every 4 wks (10 IV → 75 SC); s.c. secukinumab 150 mg every 4 wks (10 IV → 150 SC); or PBO on the same i.v. and s.c. schedules. MRI of the SI joints and spine were performed on a subset of 105 subjects with no prior exposure to therapies targeting tumor necrosis factor (anti–TNF-naïve). Assessments were completed at baseline, Wks 16 and 52. MRI variables were assessed by the Berlin SI joint total edema score, MRI score for spinal activity (ASspi-MRI-a), and the Berlin spine score (derived from the ASspi-MRI-a results). Two experienced readers, blinded to treatment and visit, evaluated all MRIs and their mean scores were used for the final analyses.

Results Mean baseline ASspi-MRI-a and Berlin spine scores were lower in the secukinumab 10 IV → 150 SC group than in the 10 IV → 75 SC and PBO groups (Table). At Wk 16, improvements were shown in Berlin SI joint total edema score with secukinumab vs PBO (mean change from baseline: –1.30 and –1.05 vs –0.17 in secukinumab 10 IV → 150 SC and 10 IV → 75 SC vs PBO groups, respectively; P <0.01) (Table). Both secukinumab doses also resulted in greater mean percentage improvements from baseline in ASspi-MRI-a and Berlin spine scores vs PBO (Table). Improvements in all MRI measures with secukinumab were sustained through Wk 52.

Conclusions MRI measures demonstrate that secukinumab provides early reductions in spinal inflammation in subjects with active AS, and that these improvements are sustained through 52 wks of therapy.

References

  1. Baeten D, et al. Arthritis Rheumatol. 2014;66(Suppl):S360

Acknowledgements Medical writing support was provided by Jessica Breen at Seren Communications (Tytherington, UK), and was funded by Novartis.

Disclosure of Interest X. Baraliakos Grant/research support from: AbbVie, Merck, Pfizer, UCB, Novartis, and Chugai, Consultant for: AbbVie, Merck, Pfizer, UCB, Novartis, and Chugai, Speakers bureau: AbbVie, Merck, Pfizer, UCB, Novartis, and Chugai, J. Braun Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB, Consultant for: Abbvie (Abbott), Amgen, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB, Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer-Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB, J. Sieper Grant/research support from: AbbVie, Pfizer, and Merck, Consultant for: AbbVie, Pfizer, Merck, UCB, and Novartis, Speakers bureau: AbbVie, Pfizer, Merck, and UCB, D. Baeten Grant/research support from: Boehringer-Ingelheim, Janssen, MSD, Novartis, and Pfizer, Consultant for: AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, A. Readie Shareholder of: Novartis, Employee of: Novartis, G. Ligozio Shareholder of: Novartis, Employee of: Novartis, H. Richards Employee of: Novartis

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.